Teknova Finalizes $40M Offering at $5.00, 12% Below Pre-Deal Price
TKNO has more than doubled off its 52-week low of $1.91 on elevated volume (17× avg).
Summary
Teknova priced a final $40 million underwritten offering of 8 million shares at $5.00, roughly 12% below the pre-deal reference price, adding about 15% to the share count and $3.58 per share of book-value dilution to new buyers.
Key Events · Financing and Capital Events · TKNO
-
8M Shares Priced at $5.00
Underwritten offering of 8,000,000 shares at $5.00 for $40.0M gross; underwriters hold a 30-day option on 1,200,000 more shares, taking the maximum to $46.0M.
-
Net Proceeds and Fees
Net proceeds of $37.6M ($43.2M with full greenshoe) after a $0.30/share, 6.0% underwriting discount ($2.4M) and about $380,000 of estimated expenses.
-
Dilution to New Buyers
As-adjusted net tangible book value rises to $1.42 per share from $0.93, leaving $3.58 per share of immediate dilution to offering participants; post-deal shares outstanding are 61,702,534 versus 53,702,534 at September 30, 2026.
-
Use of Proceeds
General corporate purposes, potentially including repayment of a portion of the MidCap credit facility; no specific allocation committed.
Analysis · TKNO · Life Sciences
The deal is done: Teknova is selling 8 million new shares at $5.00 to raise $40 million gross ($37.6 million net after a 6% underwriting discount), with a 1.2 million-share greenshoe that could push the total to $46 million. That price sits about 12% below the $5.70 reference level around announcement and well under the $6.80 last sale on October 19, so the company conceded ground to get the deal done. Existing holders absorb roughly 15% more shares (8.0M on 53.7M outstanding), and new buyers take $3.58 per share of immediate book-value dilution. The cash matters: $16.6 million on hand at September 30 against a still-negative adjusted EBITDA of $1.0-1.2 million a quarter means this raise extends the runway materially, and management flagged possible debt repayment under the MidCap facility. The offsetting read is that a discounted raise right after a strong Q3 pre-announcement (revenue up 19-21%) suggests the equity was priced for certainty rather than demand.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TKNO was trading at $5.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $314.1M. The 52-week trading range was $1.91 to $9.48. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.